Published in Blood on February 01, 2001
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant (2014) 1.88
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant (2012) 1.80
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant (2007) 1.74
Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant (2009) 1.68
Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood (2010) 1.62
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 1.55
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant (2008) 1.51
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2008) 1.27
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19
Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol (2010) 1.16
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood (2014) 1.14
Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag (2009) 1.12
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.10
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant (2009) 1.10
NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol (2010) 1.08
Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant (2007) 1.07
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.07
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica (2014) 1.07
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol (2012) 1.02
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen (2010) 0.99
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma (2012) 0.96
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys (2012) 0.95
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.92
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol (2009) 0.91
How to manage the transplant question in myelofibrosis. Blood Cancer J (2012) 0.89
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 0.89
Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol (2004) 0.89
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant (2013) 0.86
Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. Korean J Hematol (2010) 0.84
Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.83
Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant (2007) 0.83
Cord Blood Transplantation: Can We Make it Better? Front Oncol (2013) 0.81
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Hematopoietic cell transplantation for treatment of primary immune deficiencies. Cell Ther Transplant (2010) 0.80
Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol (2005) 0.80
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplant (2013) 0.80
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant (2015) 0.79
Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk (2011) 0.78
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci (2007) 0.78
Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity? Curr Pharmacogenomics Person Med (2010) 0.77
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant (2015) 0.76
Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology (2003) 0.76
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID. Bone Marrow Transplant (2011) 0.76
A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. Bone Marrow Transplant (2014) 0.76
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen. Med Sci Monit (2011) 0.75
Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience. Curr Oncol (2014) 0.75
Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients. Mol Clin Oncol (2016) 0.75
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies. Bone Marrow Transplant (2015) 0.75
Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Oncotarget (2016) 0.75
The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol (2009) 0.75
The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation. Intern Med (2016) 0.75
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen. Int J Clin Oncol (2009) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 24.57
MINIATURE escherichia coli CELLS DEFICIENT IN DNA. Proc Natl Acad Sci U S A (1967) 19.02
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell (1996) 16.73
Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (1997) 16.09
Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell (1998) 13.87
Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (2000) 13.62
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell (1997) 12.83
Orchestrated transcription of key pathways in Arabidopsis by the circadian clock. Science (2000) 12.35
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev (1998) 11.86
Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med (2000) 11.35
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell (1980) 10.35
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Exposure measurement error in time-series studies of air pollution: concepts and consequences. Environ Health Perspect (2000) 9.30
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol (1999) 8.21
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell (1993) 6.95
An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem (1999) 6.88
HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J Mol Graph (1996) 6.48
Endonuclease G is an apoptotic DNase when released from mitochondria. Nature (2001) 6.20
Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med (1994) 6.05
DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell (1997) 5.95
Identification of a point mutation in the voltage-gated sodium channel gene of Kenyan Anopheles gambiae associated with resistance to DDT and pyrethroids. Insect Mol Biol (2000) 5.81
Effects of colchicine and related substances on cell division. Biochem J (1936) 5.80
Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res (2001) 5.78
Speech recognition in noise as a function of the number of spectral channels: comparison of acoustic hearing and cochlear implants. J Acoust Soc Am (2001) 5.75
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
Mechanisms of fear extinction. Mol Psychiatry (2006) 5.44
Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc Natl Acad Sci U S A (2000) 5.38
Absorption of guinea pig serum with agar. A method for elimination of itscytotoxicity for murine thymus cells. Transplantation (1970) 5.37
DNA microarray-mediated transcriptional profiling of the Escherichia coli response to hydrogen peroxide. J Bacteriol (2001) 5.35
Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci (2001) 4.99
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature (1998) 4.89
Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med (2001) 4.71
Antibody diversity: somatic hypermutation of rearranged VH genes. Cell (1981) 4.65
SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A (1993) 4.61
POWER_SAGE: comparing statistical tests for SAGE experiments. Bioinformatics (2000) 4.56
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Noninvasive imaging of in vivo blood flow velocity using optical Doppler tomography. Opt Lett (1997) 4.48
Geobacter sulfurreducens sp. nov., a hydrogen- and acetate-oxidizing dissimilatory metal-reducing microorganism. Appl Environ Microbiol (1994) 4.44
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
Mouse actin messenger RNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse alpha-actin mRNA. J Biol Chem (1981) 4.30
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res (1999) 4.23
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol (1996) 4.11
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem (1998) 4.02
Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med (1992) 3.95
Interstitial cells of Cajal mediate cholinergic neurotransmission from enteric motor neurons. J Neurosci (2000) 3.95
Association of the Arabidopsis CTR1 Raf-like kinase with the ETR1 and ERS ethylene receptors. Proc Natl Acad Sci U S A (1998) 3.94
Multiple transcription-factor genes are early targets of phytochrome A signaling. Proc Natl Acad Sci U S A (2001) 3.91
Language comprehension in language-learning impaired children improved with acoustically modified speech. Science (1996) 3.84
The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A (1998) 3.83
Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes. J Bacteriol (1998) 3.81
Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci (2001) 3.71
Self-terminating diffraction gates femtosecond X-ray nanocrystallography measurements. Nat Photonics (2012) 3.68
Structural basis of IAP recognition by Smac/DIABLO. Nature (2001) 3.66
Temporal and rate representations of time-varying signals in the auditory cortex of awake primates. Nat Neurosci (2001) 3.62
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 3.59
Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (2000) 3.54
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Dark is a Drosophila homologue of Apaf-1/CED-4 and functions in an evolutionarily conserved death pathway. Nat Cell Biol (1999) 3.45
Association of Rab25 and Rab11a with the apical recycling system of polarized Madin-Darby canine kidney cells. Mol Biol Cell (1999) 3.45
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. Cell (2000) 3.39
Myocyte death in the failing human heart is gender dependent. Circ Res (1999) 3.38
The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem (1996) 3.38
A clinical trial of active management of labor. N Engl J Med (1995) 3.34
Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A (2000) 3.32
Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology (1995) 3.26
High molecular gas fractions in normal massive star-forming galaxies in the young Universe. Nature (2010) 3.18
Definition of subchromosomal intervals around the myotonic dystrophy gene region at 19q. Genomics (1989) 3.16
Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1). J Biol Chem (1994) 3.09
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem (1993) 3.04
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest (1997) 2.93
Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci (1997) 2.90